Memantine: Updating a rare success story in pro-cognitive therapeutics.
Alzheimer's disease
Learning and memory
Memantine
NMDA receptor
Neuroprotection
Synaptic plasticity
Journal
Neuropharmacology
ISSN: 1873-7064
Titre abrégé: Neuropharmacology
Pays: England
ID NLM: 0236217
Informations de publication
Date de publication:
11 Oct 2023
11 Oct 2023
Historique:
received:
16
02
2023
revised:
25
09
2023
accepted:
26
09
2023
pubmed:
14
10
2023
medline:
14
10
2023
entrez:
13
10
2023
Statut:
aheadofprint
Résumé
The great potential for NMDA receptor modulators as druggable targets in neurodegenerative disorders has been met with limited success. Considered one of the rare exceptions, memantine has consistently demonstrated restorative and prophylactic properties in many AD models. In clinical trials memantine slows the decline in cognitive performance associated with AD. Here, we provide an overview of the basic properties including pharmacological targets, toxicology and cellular effects of memantine. Evidence demonstrating reductions in molecular, physiological and behavioural indices of AD-like impairments associated with memantine treatment are also discussed. This represents both an extension and homage to Dr. Chris Parson's considerable contributions to our fundamental understanding of a success story in the AD treatment landscape.
Identifiants
pubmed: 37832633
pii: S0028-3908(23)00327-1
doi: 10.1016/j.neuropharm.2023.109737
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
109737Informations de copyright
Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest Parisa Karimi Tari: none. Chris G. Parsons: none. Graham L. Collingridge: none. Gerhard Rammes: none.